CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

Stock Information for CASI Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
CASI Pharmaceuticals Announces Changes in Board Governance
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.